Published • loading... • Updated
Boehringer licenses PVT virus platform for cancer vaccines - European Biotechnology Magazine
Summary by European-biotechnology.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Boehringer licenses PVT virus platform for cancer vaccines - European Biotechnology Magazine
Boehringer Ingelheim has licensed oncology rights to Prime Vector Technologies’ (PVT) Orf virus platform to develop a new generation of cancer vaccines. The post Boehringer licenses PVT virus platform for cancer vaccines appeared first on European Biotechnology Magazine.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
